FOXC2 promotes epithelial–mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells

被引:0
作者
Yuwen He
Hui Xie
Pengjiu Yu
Shunjun Jiang
Li Wei
机构
[1] The First Affiliated Hospital of Guangzhou Medical University,Department of Pharmacy
来源
Cancer Chemotherapy and Pharmacology | 2018年 / 82卷
关键词
FOXC2; Non-small cell lung cancer; Epithelial–mesenchymal transition; Cisplatin resistance; Snail;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1049 / 1059
页数:10
相关论文
共 301 条
[21]  
Vahdat LT(2015)FOXF2 suppresses the FOXC2-mediated epithelial–mesenchymal transition and multidrug resistance of basal-like breast cancer Cancer Lett 367 129-75
[22]  
Altorki NK(2017)Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2 Cancer Lett 396 66-2720
[23]  
Mittal V(2014)SET-mediated NDRG1 inhibition is involved in acquisition of epithelial-to-mesenchymal transition phenotype and cisplatin resistance in human lung cancer cell Cell Signal 26 2710-50
[24]  
Gao D(2016)Cisplatin in the modern era: the backbone of first-line chemotherapy for non-small cell lung cancer Cancer Treatment Rev 44 42-443
[25]  
Singh A(2013)MiR-520 h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol Oncogene 32 431-94
[26]  
Settleman J(2014)FOXC2 promotes colorectal cancer proliferation through inhibition of FOXO3a and activation of MAPK and AKT signaling pathways Cancer Lett 353 87-535
[27]  
Lazarova D(2008)The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy Annu Rev Pharmacol Toxicol 48 495-726
[28]  
Bordonaro M(2013)Cancer drug resistance: an evolving paradigm Nat Rev Cancer 13 714-6
[29]  
Wang X(2016)Transition to resistance: an unexpected role of the EMT in cancer chemoresistance Genes Dis 3 3-2360
[30]  
Ling MT(2011)Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells Clin Cancer Res 17 2350-1403